Mechanisms of immune tolerance induction of tumour cells in chronic lymphocytic leukaemia and possibilityof their detection using flow cytometry

1. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94(6): 1840-1847.

2. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenviroment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 144(16): 3367-3375.

3. Stevenson BK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118(16): 4313-4320.

4. Wienster A. Emerging role of kinase targeted strategie in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 88-96.

5. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12(3): 229-243.

6. Duhren- von Minden MD, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signaling. Nature 2012; 489(7415): 309-312.

7. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99(24): 15524-15529.

8. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10(1): 37-50.

9. Sharp AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126.

10. Wherry EJ. T-cell exhaustion. Nat Immunol 2011; 12(6): 492-432.

11. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T-cell exhaustion my multiple inhibitory receptor during chronic viral infection. Nat Immunol 2009; 10(1): 29-37.

12. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121: 1612-1612 .

13. Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-1L expresion in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patiens. Leukemia 2009; 23(2): 375-382.

14. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114(8): 1528-1536.

15. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alter CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77(8): 4911-4927.

16. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177(1): 213-218.

17. Digel W, Stefanic M, Schoniger W, et al. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989;73(5):1242-1246.

18. Ahmadzadeh M, Felipe–Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112: 4953-4960.

19. Juan XL, Chen L, Li MX, et al. Elevated expresion of Foxp3 in tumor-infiltrating Treg supresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol 2010; 134: 277-288.

20. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111: 5359-5370.

21. Ai WZ, Hou JZ, Zeiser R, et al. Follicular lymphoma B cells induce the conversion of conventional CD4+ Tcells to T-regulatory cells. Int J Cancer 2009;124:239-244.

22. J. Wang, Ke X. The Four types of Tregs in malignant lymphomas. Journal of Hematology & Oncology 2011; 4(50): 1-10.

23. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24: 209-226.

24. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005; 102(14): 5138-5143.

25. Lopes JE, Torgerson TR, Schubert LA, et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol 2006; 177(5): 3133-3142.

26. Ono M,Yaguchi H, Ohkura N, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007; 446(7136): 685-689.

27. Liu W, Putnam AL, Xu-yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. JEM 2006; 203(7): 1701-1711.

28. Hofmeister R, Khaled AR, Benbernou N, et al. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 1999; 10(1): 41-60.

29. Appasamy PM. Biological and clinical implications of interleukin-7 and lymphopoiesis. Cytokines Cell Mol Ther 1999; 5(1): 25-39.

30. Weiss L, Melchardt T, Egle A, Grabmer C, Greil R. and Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011; 117: 2163-2169.

31. Lad DP, Varma S, Varma N, et al. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias Leukemia and lymphoma 2013; 54(5): 1012-1019.

32. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host imunity in T-cell lymfoproliferative disorders. Blood 2009; 114: 2149-2158.

33. Keir ME, Butte MJ, Freemann GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.

34. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007; 30: 251-260.

35. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009; 229: 145-151.

36. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freemann GJ. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.

37. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-1L axis modulates the natural killer cell versus multiple myeloma effect: a therapeutical target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294.

38. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumotal CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.

39. Han Y, Wu J, Bi L, et al. Malignant B cells induce the conversion of CD4CD25 T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PloS One. Publikováno elektronicky 2011; 6:e28649.

40. Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enthances ex vivo T-cell responses to autologous dendritic cells/myeloma fusion vaccine. J Immunother 2011; 34: 409-418.

41. Azuma T, Yao S, Zhu G, Flies SJ, Chen L. B7-H1 is ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111: 3635-3643.

42. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clinical and Developmental Immunology Publikováno elektronicky 656340. Epub 2012 Apr 29.

43. Green M, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p22.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116(17): 3268-3277.

44. Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1 infected patients. J Acquir Immune Defic Syndr 2010; 54(5): 447–454.

45. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103(1): 4251-4258.

46. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(25): 1937-1947.

47. Cycon AK, Rimsza LM, Murphy SP. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Exp Hematol 2009; 7(2): 184-194.

48. Steidl CH, Gascoyne R. The molecular pathogenesis of primary mediastinal large B-cell. Blood 2011; 118(10): 2659-2669.

49. Steidl CH, Shan SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471(7338): 377-383.

50. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-245.

51. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800 [Erratum, Nat Med 2002; 8: 1039].

52. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757-1766.

53. Taube JM, Anders RA, Young JD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.

54. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10: 1185-1192.

55. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99: 12293-12297.

56. Mittal AK, Chaturvedi NK, Rohlfsen RA, et al. Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia. PLoS ONE 2013 8(8): e70352. doi:10.1371/journal.pone.0070352.

57. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107: 4275–80.

58. Topalian SL, Hodi FS,Brahmer JR, at al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer, N Engl J Med 2012; 366: 2443-2454.

59. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15: 69-77.

60. Van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.

61. Maher KJ, Fletcher MA. Quantitative flow cytometry in the clinical laboratory. Clinical and Applied Immunology Reviews 2005; 5(6): 353–372.

62. Klabusay M, Sukova V, Coupek P. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry 2007; 72B: 363–370. doi: 10.1002/cyto.b.20181.

63. Porter DL, Levine BL, Kalos M, et al. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia N Engl J Med 2011; 365:725-733. doi: 10.1056/NEJMoa1103849.

64. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117(5): 1167–1174.

65. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-212.

66. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood; 2013: 138-150.